{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:07:42Z","timestamp":1791360462268,"version":"4.3.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K23AG059888"],"award-info":[{"award-number":["K23AG059888"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K23AG076960"],"award-info":[{"award-number":["K23AG076960"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P30-AG062422"],"award-info":[{"award-number":["P30-AG062422"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P30-AG062422"],"award-info":[{"award-number":["P30-AG062422"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K99AG065501"],"award-info":[{"award-number":["K99AG065501"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"crossref","award":["AACSF:19-617663"],"award-info":[{"award-number":["AACSF:19-617663"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"crossref","award":["AARF:16-443577"],"award-info":[{"award-number":["AARF:16-443577"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016608","name":"Rainwater Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Plasma phosphorylated tau (p-tau) has emerged as a promising biomarker for Alzheimer\u2019s disease (AD). Studies have reported strong associations between p-tau and tau-PET that are mainly driven by differences between amyloid-positive and amyloid-negative patients. However, the relationship between p-tau and tau-PET is less characterized within cognitively impaired patients with a biomarker-supported diagnosis of AD. We conducted a head-to-head comparison between plasma p-tau217 and tau-PET in patients at the clinical stage of AD and further assessed their relationships with demographic, clinical, and biomarker variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively included 87 amyloid-positive patients diagnosed with MCI or dementia due to AD who underwent structural MRI, amyloid-PET (\n                      <jats:sup>11<\/jats:sup>\n                      C-PIB), tau-PET (\n                      <jats:sup>18<\/jats:sup>\n                      F-flortaucipir, FTP), and blood draw assessments within 1\u00a0year (age\u2009=\u200966\u2009\u00b1\u200910, 48% female). Amyloid-PET was quantified in Centiloids (CL) while cortical tau-PET binding was measured using standardized uptake value ratios (SUVRs) referenced against inferior cerebellar cortex. Plasma p-tau217 concentrations were measured using an electrochemiluminescence-based assay on the Meso Scale Discovery platform. MRI-derived cortical volume was quantified with FreeSurfer. Mini-Mental State Examination (MMSE) scores were available at baseline (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200985) and follow-up visits (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928; 1.5\u2009\u00b1\u20090.7\u00a0years).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Plasma p-tau217 and cortical FTP-SUVR were correlated (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.61,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.001), especially in temporo-parietal and dorsolateral frontal cortices. Both higher p-tau217 and FTP-SUVR values were associated with younger age, female sex, and lower cortical volume, but not with APOE-\u03b54 carriership. PIB-PET Centiloids were weakly correlated with FTP-SUVR (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.26,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02), but not with p-tau217 (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.10,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.36). Regional PET-plasma associations varied with amyloid burden, with p-tau217 being more strongly associated with tau-PET in temporal cortex among patients with moderate amyloid-PET burden, and with tau-PET in primary cortices among patients with high amyloid-PET burden. Higher p-tau217 and FTP-SUVR values were independently associated with lower MMSE scores cross-sectionally, while only baseline FTP-SUVR predicted longitudinal MMSE decline when both biomarkers were included in the same model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Plasma p-tau217 and tau-PET are strongly correlated in amyloid-PET-positive patients with MCI or dementia due to AD, and they exhibited comparable patterns of associations with demographic variables and with markers of downstream neurodegeneration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-023-01302-w","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T08:02:57Z","timestamp":1695369777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment"],"prefix":"10.1186","volume":"15","author":[{"given":"Nidhi S.","family":"Mundada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawren","family":"Vandevrede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth H.","family":"Thijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obiora C.","family":"Okoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjani","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Soleimani-Meigooni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argentina L.","family":"Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Heuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howie J.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Dage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Jagust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil D.","family":"Rabinovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"La Joie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"1302_CR1","first-page":"9","volume-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","author":"MM Mielke","year":"2018","unstructured":"Mielke MM. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. 2018. p. 9."},{"key":"1302_CR2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26:20.","journal-title":"Nat Med"},{"key":"1302_CR3","first-page":"10","volume-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. 2020. p. 10."},{"key":"1302_CR4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387\u201397.","journal-title":"Nat Med"},{"key":"1302_CR5","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114022","volume":"13","author":"N Mattsson-Carlgren","year":"2021","unstructured":"Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med. 2021;13: e14022.","journal-title":"EMBO Mol Med"},{"key":"1302_CR6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422\u201333.","journal-title":"Lancet Neurol"},{"key":"1302_CR7","doi-asserted-by":"publisher","unstructured":"Thijssen EH. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20:739\u201352. https:\/\/doi.org\/10.1016\/S1474-4422(21)00214-3.","DOI":"10.1016\/S1474-4422(21)00214-3"},{"key":"1302_CR8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/alz.12301","volume":"17","author":"AM Brickman","year":"2021","unstructured":"Brickman AM, Manly JJ, Honig LS, Sanchez D, Reyes-Dumeyer D, Lantigua RA, et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 2021;17:1353\u201364.","journal-title":"Alzheimers Dement"},{"key":"1302_CR9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141:709\u201324.","journal-title":"Acta Neuropathol"},{"key":"1302_CR10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","volume":"140","author":"J Lantero Rodriguez","year":"2020","unstructured":"Lantero Rodriguez J, Karikari TK, Su\u00e1rez-Calvet M, Troakes C, King A, Emersic A, et al. Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 2020;140:267\u201378.","journal-title":"Acta Neuropathol"},{"key":"1302_CR11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, et al. Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 2021;78:149\u201356.","journal-title":"JAMA Neurol"},{"key":"1302_CR12","doi-asserted-by":"crossref","first-page":"103837","DOI":"10.1016\/j.ebiom.2022.103837","volume":"76","author":"C Tissot","year":"2022","unstructured":"Tissot C, Therriault J, Kunach P, Benedet AL, Pascoal TA, Ashton NJ, et al. Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. eBioMedicine. 2022;76:103837.","journal-title":"eBioMedicine"},{"key":"1302_CR13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","volume":"26","author":"TK Karikari","year":"2021","unstructured":"Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Su\u00e1rez-Calvet M, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative. Mol Psychiatry. 2021;26:429\u201342.","journal-title":"Mol Psychiatry"},{"key":"1302_CR14","doi-asserted-by":"publisher","unstructured":"Coomans EM, Verberk IMW, Ossenkoppele R, Verfaillie SCJ, Visser D, Gouda M, et al. A head-to-head comparison between plasma pTau181 and tau-PET along the Alzheimer\u2019s disease continuum. J Nucl Med. 2023;64(3):437\u201343. https:\/\/doi.org\/10.2967\/jnumed.122.264279.","DOI":"10.2967\/jnumed.122.264279"},{"key":"1302_CR15","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384:1691\u2013704.","journal-title":"N Engl J Med"},{"key":"1302_CR16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537:50\u20136.","journal-title":"Nature"},{"key":"1302_CR17","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1212\/WNL.0000000000011270","volume":"96","author":"R La Joie","year":"2021","unstructured":"La Joie R, Visani AV, Lesman-Segev OH, Baker SL, Edwards L, Iaccarino L, et al. Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET. Neurology. 2021;96:e650\u201361.","journal-title":"Neurology"},{"key":"1302_CR18","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jalz.2018.12.016","volume":"15","author":"JL Whitwell","year":"2019","unstructured":"Whitwell JL, Martin P, Graff-Radford J, Machulda MM, Senjem ML, Schwarz CG, et al. The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer\u2019s disease. Alzheimers Dement. 2019;15:675\u201385.","journal-title":"Alzheimers Dement"},{"key":"1302_CR19","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1093\/brain\/awx171","volume":"140","author":"M Sch\u00f6ll","year":"2017","unstructured":"Sch\u00f6ll M, Ossenkoppele R, Strandberg O, Palmqvist S, J\u00f6gi J, SwedishBioFINDER study, et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer\u2019s disease. Brain. 2017;140:2286\u201394.","journal-title":"Brain"},{"key":"1302_CR20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.neurobiolaging.2021.04.003","volume":"105","author":"L Edwards","year":"2021","unstructured":"Edwards L, La Joie R, Iaccarino L, Strom A, Baker SL, Casaletto KB, et al. Multimodal neuroimaging of sex differences in cognitively impaired patients on the Alzheimer\u2019s continuum: greater tau-PET retention in females. Neurobiol Aging. 2021;105:86\u201398.","journal-title":"Neurobiol Aging"},{"key":"1302_CR21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neurobiolaging.2021.05.013","volume":"107","author":"SJ Banks","year":"2021","unstructured":"Banks SJ, Andrews MJ, Digma L, Madsen J, Reas ET, Caldwell JZK, et al. Sex differences in Alzheimer\u2019s disease: do differences in tau explain the verbal memory gap? Neurobiol Aging. 2021;107:70\u20137.","journal-title":"Neurobiol Aging"},{"key":"1302_CR22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1212\/WNL.0000000000002892","volume":"87","author":"H Cho","year":"2016","unstructured":"Cho H, Choi JY, Hwang MS, Lee JH, Kim YJ, Lee HM, et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology. 2016;87:375\u201383.","journal-title":"Neurology"},{"key":"1302_CR23","doi-asserted-by":"crossref","first-page":"eaau5732","DOI":"10.1126\/scitranslmed.aau5732","volume":"12","author":"R La Joie","year":"2020","unstructured":"La Joie R, Visani AV, Baker SL, Brown JA, Bourakova V, Cha J, et al. Prospective longitudinal atrophy in Alzheimer\u2019s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020;12:eaau5732.","journal-title":"Sci Transl Med"},{"key":"1302_CR24","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","volume":"78","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78:961\u201371.","journal-title":"JAMA Neurol"},{"key":"1302_CR25","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772\u201381.","journal-title":"JAMA"},{"key":"1302_CR26","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1212\/WNL.0000000000004860","volume":"90","author":"R La Joie","year":"2018","unstructured":"La Joie R, Bejanin A, Fagan AM, Ayakta N, Baker SL, Bourakova V, et al. Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology. 2018;90:e282\u201390.","journal-title":"Neurology"},{"key":"1302_CR27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement"},{"key":"1302_CR28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"1302_CR29","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","volume":"157","author":"A Maass","year":"2017","unstructured":"Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer\u2019s disease. Neuroimage. 2017;157:448\u201363.","journal-title":"Neuroimage"},{"key":"1302_CR30","doi-asserted-by":"crossref","first-page":"102025","DOI":"10.1016\/j.nicl.2019.102025","volume":"24","author":"OH Lesman-Segev","year":"2019","unstructured":"Lesman-Segev OH, La Joie R, Stephens ML, Sonni I, Tsai R, Bourakova V, et al. Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy. Neuroimage Clin. 2019;24:102025.","journal-title":"Neuroimage Clin"},{"key":"1302_CR31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ana.25968","volume":"89","author":"OH Lesman-Segev","year":"2021","unstructured":"Lesman-Segev OH, La Joie R, Iaccarino L, Lobach I, Rosen HJ, Seo SW, et al. Diagnostic accuracy of amyloid versus 18 F-fluorodeoxyglucose positron emission tomography in autopsy-confirmed dementia. Ann Neurol. 2021;89:389\u2013401.","journal-title":"Ann Neurol"},{"key":"1302_CR32","doi-asserted-by":"crossref","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","volume":"6","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, et al. A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer\u2019s disease. Sci Adv. 2020;6:eaaz2387.","journal-title":"Sci Adv"},{"key":"1302_CR33","doi-asserted-by":"publisher","unstructured":"Ferreira PCL, Therriault J, Tissot C, Ferrari-Souza JP, Benedet AL, Povala G, et al. Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individuals. Alzheimer\u2019s Dementia. [cited 9 Aug 2023];n\/a. Available from: https:\/\/doi.org\/10.1002\/alz.13393","DOI":"10.1002\/alz.13393"},{"key":"1302_CR34","doi-asserted-by":"crossref","first-page":"e12321","DOI":"10.1002\/dad2.12321","volume":"14","author":"K Berry","year":"2022","unstructured":"Berry K, Asken BM, Grab JD, Chan B, Lario Lago A, Wong R, et al. Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology. Alzheimers Dement (Amst). 2022;14:e12321.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1302_CR35","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, Dage JL, Frank RD, Algeciras-Schimnich A, Knopman DS, Lowe VJ, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022;28:1398\u2013405.","journal-title":"Nat Med"},{"key":"1302_CR36","doi-asserted-by":"crossref","unstructured":"Pichet Binette A, Janelidze S, Cullen N, Dage JL, Bateman RJ, Zetterberg H, et al. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 2023;19:1403\u201314.","DOI":"10.1002\/alz.12787"},{"key":"1302_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer\u2019s Dementia. 2015;11:1\u201315.e4.","journal-title":"Alzheimer\u2019s Dementia"},{"key":"1302_CR38","doi-asserted-by":"crossref","unstructured":"Ossenkoppele R, Reimand J, Smith R, Leuzy A, Strandberg O, Palmqvist S, et al. Tau PET correlates with different Alzheimer\u2019s disease-related features compared to CSF and plasma p-tau biomarkers. EMBO Mol Med. 2021;13(8):e14398.","DOI":"10.15252\/emmm.202114398"},{"key":"1302_CR39","doi-asserted-by":"crossref","unstructured":"Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, et al. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurology. 2022;79:1250\u201359.","DOI":"10.1001\/jamaneurol.2022.3392"},{"key":"1302_CR40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","volume":"112","author":"H Braak","year":"2006","unstructured":"Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389\u2013404.","journal-title":"Acta Neuropathol"},{"key":"1302_CR41","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/s41467-020-15701-2","volume":"11","author":"JW Vogel","year":"2020","unstructured":"Vogel JW, Iturria-Medina Y, Strandberg OT, Smith R, Levitis E, Evans AC, et al. Spread of pathological tau proteins through communicating neurons in human Alzheimer\u2019s disease. Nat Commun. 2020;11:2612.","journal-title":"Nat Commun"},{"key":"1302_CR42","doi-asserted-by":"crossref","first-page":"e1823","DOI":"10.1212\/WNL.0000000000012775","volume":"97","author":"SE Schindler","year":"2021","unstructured":"Schindler SE, Li Y, Buckles VD, Gordon BA, Benzinger TLS, Wang G, et al. Predicting symptom onset in sporadic Alzheimer disease with amyloid PET. Neurology. 2021;97:e1823\u201334.","journal-title":"Neurology"},{"key":"1302_CR43","first-page":"e12007","volume":"12","author":"RL Koscik","year":"2020","unstructured":"Koscik RL, Betthauser TJ, Jonaitis EM, Allison SL, Clark LR, Hermann BP, et al. Amyloid duration is associated with preclinical cognitive decline and tau PET. Alzheimers Dement (Amst). 2020;12:e12007.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1302_CR44","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/brain\/awab099","volume":"144","author":"S Spina","year":"2021","unstructured":"Spina S, La Joie R, Petersen C, Nolan AL, Cuevas D, Cosme C, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer\u2019s disease. Brain. 2021;144:2186\u201398.","journal-title":"Brain"},{"key":"1302_CR45","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1212\/WNL.0000000000013107","volume":"98","author":"DS Smirnov","year":"2022","unstructured":"Smirnov DS, Salmon DP, Galasko D, Goodwill VS, Hansen LA, Zhao Y, et al. Association of neurofibrillary tangle distribution with age at onset-related clinical heterogeneity in Alzheimer disease: an autopsy study. Neurology. 2022;98:e506\u201317.","journal-title":"Neurology"},{"key":"1302_CR46","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/jamaneurol.2019.4421","volume":"77","author":"J Therriault","year":"2020","unstructured":"Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Chamoun M, Savard M, et al. Association of apolipoprotein E \u03b54 with medial temporal tau independent of amyloid-\u03b2. JAMA Neurol. 2020;77:470\u20139.","journal-title":"JAMA Neurol"},{"key":"1302_CR47","doi-asserted-by":"crossref","first-page":"eabc0655","DOI":"10.1126\/scitranslmed.abc0655","volume":"13","author":"JS Sanchez","year":"2021","unstructured":"Sanchez JS, Becker JA, Jacobs HIL, Hanseeuw BJ, Jiang S, Schultz AP, et al. The cortical origin and initial spread of medial temporal tauopathy in Alzheimer\u2019s disease assessed with positron emission tomography. Sci Transl Med. 2021;13:eabc0655.","journal-title":"Sci Transl Med"},{"key":"1302_CR48","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139:1551\u201367.","journal-title":"Brain"},{"key":"1302_CR49","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/brain\/awx243","volume":"140","author":"A Bejanin","year":"2017","unstructured":"Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer\u2019s disease. Brain. 2017;140:3286\u2013300.","journal-title":"Brain"},{"key":"1302_CR50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13195-022-01105-5","volume":"14","author":"D Biel","year":"2022","unstructured":"Biel D, Luan Y, Brendel M, Hager P, Dewenter A, Moscoso A, et al. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2022;14:166.","journal-title":"Alzheimer\u2019s Res Ther"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-023-01302-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-023-01302-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-023-01302-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T17:26:31Z","timestamp":1700241991000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-023-01302-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1302"],"URL":"https:\/\/doi.org\/10.1186\/s13195-023-01302-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.11.29.22282851","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"assertion":[{"value":"6 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients provided written, informed consent at the time of recruitment. The study was approved by the institutional review boards at UCSF, University of California, Berkeley, and Lawrence Berkeley National Laboratory.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NSM, EHT RS, DSM have nothing to disclose.JCR is a site PI for clinical trials sponsored by Eisai and Eli Lilly.LI is a full-time employee and minor stockholder of Eli Lilly and Company at the time of manuscript submission, although he was a UCSF employee during his involvement in the study.CET receives support from the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND (IMI 2 Joint Undertaking (JU), grant No. 101034344) and JPND (bPRIDE), National MS Society (Progressive MS alliance), Alzheimer Association, Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands. CT is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). CET has a collaboration contract with ADx Neurosciences, Quanterix and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Fujirebio, Grifols, Instant Nano Biosensors, Merck, Novo Nordisk, PeopleBio, Roche, Siemens, Toyama, Vivoryon. She had speaker contracts for Roche, Grifols, Novo Nordisk. She serves on editorial boards of Medidact Neurologie\/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & Neuroinflammation.BLM receives research support from the NIH\/NIA and the Centers for Medicare & Medicaid Services (CMS) as grants for the Memory and Aging Center. As an additional disclosure, Dr. Miller serves as Medical Director for the John Douglas French Foundation; Scientific Director for the Tau Consortium; Director\/Medical Advisory Board of the Larry L. Hillblom Foundation; Scientific Advisory Board Member for the National Institute for Health Research Cambridge Biomedical Research Centre and its subunit, the Biomedical Research Unit in Dementia (UK); and Board Member for the American Brain Foundation (ABF).JLD is an inventor on patents or patent applications of Eli Lilly and Company relating to the assays, methods, reagents and \/ or compositions of matter related to measurement of P-tau217. He has served as a consultant for Genotix Biotechnologies Inc, Gates Ventures, Karuna Therapeutics, AlzPath Inc, Cognito Therapeutics, Inc., and received research support from ADx Neurosciences, AlzPath, Roche Diagnostics and Eli Lilly and Company in the past two years. He has received speaker fees from Eli Lilly and Company.WJJ receives research support from NIH\/NIA, Roche\/Genentech. He has received consulting fees from Bioclinica, Lilly, Eisai, and Biogen.GDR receives research support from Avid Radiopharmaceuticals, GE Healthcare, Genentech and Life Molecular Imaging, and has received consulting fees or speaking honoraria from Eli Lilly, GE Healthcare, Johnson & Johnson, Roche, Genentech, Merck. He is an associate editor of JAMA Neurology.ALB receives research support from NIH, the Rainwater Charitable Foundation, the Association for Frontotemporal Degeneration, Bluefield Project to Cure Frontotemporal Dementia, the GHR Foundation, the Alzheimer\u2019s Drug Discovery Foundation, and the Alzheimer's Association. He has served as a consultant for Aeovian, AGTC, Alector, Arkuda, Arvinas, Boehringer Ingelheim, Denali, GSK, Life Edit, Humana, Oligomerix, Oscotec, Roche, TrueBinding and Wave, and received research support from Biogen, Eisai and Regeneron.RLJ is an associate editor for Alzheimer\u2019s Research & Therapy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}